Changes to Act on Medical Products Threaten Slovene Pharmaceutical Industry, Krka Says

Ljubljana, 16 January - The proposed changes to the Medical Products Act, which would introduce a longer, six-year transitional period for the sale of generic drugs in Slovenia, is a clear attempt to disrupt the successful development of the Slovene industry of generic drugs, Milos Kovacic, chairman of the board of the pharmaceutical company Krka, said Wednesday, one day before the Parliament is to discuss the changes at an extraordinary session.